Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more
Kamada (KMDA) - Total Liabilities
Latest total liabilities as of December 2025: $109.66 Million USD
Based on the latest financial reports, Kamada (KMDA) has total liabilities worth $109.66 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kamada - Total Liabilities Trend (2008–2025)
This chart illustrates how Kamada's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kamada Competitors by Total Liabilities
The table below lists competitors of Kamada ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PDS Limited
NSE:PDSL
|
India | ₹31.60 Billion |
|
Fleetwood Ltd
AU:FWD
|
Australia | AU$91.67 Million |
|
Bellevue Group AG
SW:BBN
|
Switzerland | CHF34.51 Million |
|
Veedol Corporation Limited
NSE:VEEDOL
|
India | ₹3.52 Billion |
|
BGF Retail Co Ltd
KO:027410
|
Korea | ₩345.67 Billion |
|
Dongwon System
KO:014820
|
Korea | ₩701.13 Billion |
|
Aurelius Technologies Bhd
KLSE:5302
|
Malaysia | RM141.78 Million |
|
Adcock Ingram Holdings Limited
PINK:AIHLF
|
USA | $2.90 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Kamada's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kamada's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kamada (2008–2025)
The table below shows the annual total liabilities of Kamada from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $109.66 Million | -2.77% |
| 2024-12-31 | $112.79 Million | +1.72% |
| 2023-12-31 | $110.89 Million | -24.24% |
| 2022-12-31 | $146.36 Million | +3.18% |
| 2021-12-31 | $141.84 Million | +342.89% |
| 2020-12-31 | $32.03 Million | -16.77% |
| 2019-12-31 | $38.48 Million | +49.49% |
| 2018-12-31 | $25.74 Million | -21.09% |
| 2017-12-31 | $32.62 Million | -1.02% |
| 2016-12-31 | $32.95 Million | +11.76% |
| 2015-12-31 | $29.48 Million | -23.66% |
| 2014-12-31 | $38.62 Million | -21.83% |
| 2013-12-31 | $49.41 Million | -18.63% |
| 2012-12-31 | $60.72 Million | -3.27% |
| 2011-12-31 | $62.78 Million | -3.47% |
| 2010-12-31 | $65.03 Million | +98.51% |
| 2009-12-31 | $32.76 Million | +11.36% |
| 2008-12-31 | $29.42 Million | -- |